ClinicalTrials.gg
Not yet recruitingNCT07936643TEST4TPTUpdated Nov 13, 2026

Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda

An interventional study of Standard-of-care TB contact investigation and TPT assessment and Facility-based SIILTIBCY testing in Tuberculosis Infection, Latent and Tuberculosis Prevention, sponsored by KNCV Tuberculosis Foundation. Not yet recruiting. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by KNCV Tuberculosis Foundation · Not applicable, Interventional, and Prevention

How we know

Updated Nov 13, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,804
Allocation
Randomized
Ages
5 Years and older
Sex
All
01

Study summary

The Artificial Intelligence Assisted Innovative Low-cost Skin Testing Model to Accelerate Person-centered TB Prevention Services in Tanzania, Mozambique and Uganda (TEST4TPT) project will evaluate a person-centered approach to improve access to tuberculosis infection (TBI) testing and linkage to tuberculosis preventive treatment (TPT) in Mozambique, Tanzania, and Uganda. The project will generate evidence on the feasibility, acceptability, clinical utility, diagnostic and operational performance, and implementation of a novel point-of-care TBI testing approach, including home- or community-based testing and artificial intelligence (AI)-assisted reading. By bringing testing closer to people at increased risk of tuberculosis (TB), TEST4TPT aims to reduce barriers to care, support timely TPT initiation, and contribute to improved completion of preventive treatment.

The overall goal of TEST4TPT is to evaluate an integrated, home-based approach to TBI testing using SIILTIBCY (an authorized diagnostic skin test used to detect TBI), community health worker (CHW)-facilitated support, and AI-assisted result reading, with the aim of improving initiation and completion of TPT among close contacts of people newly diagnosed with pulmonary TB disease.

Read the detailed description

TEST4TPT is a type 2 hybrid effectiveness-implementation study designed to evaluate the effectiveness and implementation of an integrated approach to tuberculosis infection (TBI) testing and tuberculosis preventive treatment (TPT) delivery in Mozambique, Tanzania, and Uganda. The study comprises four complementary sub-studies. Sub-study 1 evaluates the performance and usability of an artificial intelligence (AI)-assisted approach for interpretation of the SIILTIBCY skin test using the SmartPatch and TBConnect application. Sub-study 2 is a pragmatic cluster-randomised trial comparing different models of TBI testing and TPT delivery, including facility- and home-based approaches. Sub-study 3 is a mixed-methods implementation evaluation examining the implementation of these approaches, including their feasibility and acceptability. Sub-study 4 comprises economic and impact assessments to evaluate the costs and broader potential impact of the approaches evaluated in the study.

The technological approach evaluated in Sub-study 1 combines the SIILTIBCY skin test with the SmartPatch and AI-driven TBConnect application. The SmartPatch is an adhesive patch applied to the participant's forearm at the site of SIILTIBCY administration. The patch contains a unique QR code used to link the participant to their record within the TBConnect platform and includes a removable circular section defining the area where the skin test is administered and subsequently read. The SmartPatch remains in place between administration and interpretation of the test.

Sub-study 1 consists of two complementary components: validation of the AI-assisted SIILTIBCY reading approach and an assessment of the usability and user experience of the SmartPatch and TBConnect system. The validation component assesses the performance and agreement of AI-assisted SIILTIBCY interpretation compared with standard interpretation by a trained healthcare worker. The usability component examines use of the technology by healthcare workers and community health workers, as well as participants' experiences of wearing the SmartPatch. A total of 330 household contacts of people with TB, aged five years or older, will participate across Mozambique, Tanzania, and Uganda.

At the follow-up visit, images of the SIILTIBCY administration site are captured through the TBConnect application for AI-assisted interpretation. The AI-assisted approach estimates the size of the induration and provides a corresponding test classification. The SmartPatch therefore supports standardised identification and imaging of the test site, while TBConnect provides the platform through which the images and AI-assisted interpretation are managed.

For validation, the AI-assisted interpretation is compared with a standard SIILTIBCY reading conducted independently by a trained healthcare worker. Both readings are performed on the same skin test and are conducted independently and under blinded conditions. The comparison evaluates the ability of the AI-assisted approach to correctly classify SIILTIBCY results and its agreement with the healthcare-worker reference reading, including agreement in the measured size of induration. During this validation sub-study, participant management and clinical decisions are based on the standard healthcare-worker reading rather than the AI-assisted result.

Sub-study 1 also assesses whether the SmartPatch and TBConnect approach is practical and acceptable to its intended users. Healthcare workers and community health workers with experience using the system are asked about its usability and its integration into routine activities, while participants provide information about their experience of wearing the SmartPatch. These findings complement the validation results by assessing not only whether the AI-assisted approach performs adequately, but also whether it can be feasibly used within the intended implementation context. Findings from Sub-study 1 will inform whether the AI-assisted approach is incorporated into the home-based testing approach evaluated in Sub-study 2.

Sub-study 2 is the main effectiveness evaluation and consists of a pragmatic cluster-randomised trial. Participating health facilities are allocated to three service-delivery approaches: standard-of-care facility-based assessment; facility-based SIILTIBCY testing and reading; or home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. The home-based arm may incorporate AI-assisted interpretation using SmartPatch and TBConnect if this approach demonstrates adequate performance in Sub-study 1. Health facilities are used as clusters to allow consistent implementation of each approach within facility workflows and minimise contamination between study arms.

Sub-study 3 evaluates the implementation of the TEST4TPT approaches using an adapted RE-AIM (Reach, Effectiveness, Adoption, Implementation and Maintenance) framework, complemented by constructs from the Implementation Outcomes Framework. The evaluation considers reach, effectiveness and clinical utility, adoption, implementation, maintenance, feasibility and acceptability. A convergent mixed-methods approach combines implementation data generated during the study with qualitative interviews involving contact persons, community health workers, healthcare workers and TB/National Tuberculosis Programmes (NTP) policymakers or programme managers. This component is intended to provide an understanding of how and why the different TBI testing and TPT delivery approaches work across different settings, alongside the effectiveness results generated in Sub-study 2.

Sub-study 4 comprises the economic and impact assessments of the TEST4TPT approaches. This component evaluates the economic implications of the different TBI testing and TPT delivery strategies and their potential impact, complementing the effectiveness and implementation findings from the other sub-studies.

02

Conditions studied

  • Tuberculosis Infection, Latent
  • Tuberculosis Prevention

Browse trials for

Keywords

  • Tuberculosis Infection
  • Tuberculosis preventive treatment
  • SIILTIBCY skin test
  • AI-assisted diagnostics
  • Contact investigation
03

In context

Latent Tuberculosis

200 studies on the registry are indexed under Latent Tuberculosis; 49 are open to participants now.

This study's planned enrollment of 1,804 is above the median of 300 across 111 interventional studies indexed under Latent Tuberculosis.

Browse Latent Tuberculosis studies →

Lead sponsor

KNCV Tuberculosis Foundation is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Reside within the catchment area of one of the participating health facilities.
  • Be a close contact, as defined by country guidelines, of a person newly diagnosed with pulmonary tuberculosis disease, irrespective of drug susceptibility.
  • Be aged ≥5 years.
  • Be able to provide written . For participants below the legal age of consent, written informed consent must be obtained from a parent or legal guardian, with participant assent obtained where required by national regulations.

Exclusion criteria

Exclusion Criteria:

  • Known to SIILTIBCY according to the manufacturer's instructions for use.
  • People with confirmed TB disease
  • Already on TPT at time of recruitment
  • Previous participation in this sub-study.
  • Presence of skin conditions at the intended injection site that may interfere with SIILTIBCY administration or interpretation of the induration (e.g. extensive dermatitis, burns, scars, or other dermatological conditions).
  • Known disease associated with .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
1,804 participants (estimated)

Study arms

  • Active comparator
    Standard of Care

    Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive routine facility-based contact investigation and assessment for eligibility for tuberculosis preventive treatment (TPT), according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included, depending on local availability and standard practice

    Other: Standard-of-care TB contact investigation and TPT assessment

  • Experimental
    Facility-based SIILTIBCY testing

    Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive facility-based SIILTIBCY testing, (an authorized diagnostic skin test used to detect TBI). SIILTIBCY is administered and subsequently read at the health facility by healthcare workers. Eligible participants are offered tuberculosis preventive treatment (TPT) according to study procedures and prevailing national guidelines.

    Diagnostic Test: Facility-based SIILTIBCY testing

  • Experimental
    Home-based SIILTIBCY testing

    Close contacts of people newly diagnosed with pulmonary tuberculosis (TB) receive home-based SIILTIBCY testing and reading delivered by community health workers, where permitted by national guidelines. Artificial Intelligence (AI)-assisted reading using the SmartPatch and TBConnect app may be incorporated if the approach is shown to be sufficiently reliable in Sub-study 1.

    Diagnostic Test: Home-based SIILTIBCY testing with SmartPatch/TBConnect AI-assisted reading, conditional on Sub-study 1 results · Device: SmartPatch reading using the TBConnect AI-assisted interpretation

Interventions

  • OtherStandard-of-care TB contact investigation and TPT assessment

    Facility-based identification and assessment of close contacts of people with pulmonary tuberculosis (TB), with assessment for tuberculosis preventive treatment (TPT) eligibility according to national guidelines. Tuberculosis infection (TBI) testing may or may not be included depending on local availability and practice.

  • Diagnostic testFacility-based SIILTIBCY testing

    Close contacts receive SIILTIBCY testing at the health facility. SIILTIBCY is administered intradermally and the test result is read 48-72 hours after administration at the health facility.

  • Diagnostic testHome-based SIILTIBCY testing with SmartPatch/TBConnect AI-assisted reading, conditional on Sub-study 1 results

    Close contacts will receive home-based tuberculosis (TB) infection screening and SIILTIBCY testing delivered by trained community health workers (CHWs), where permitted by national guidelines. CHWs will return to the household 48-72 hours after SIILTIBCY administration to assess the test result. AI-assisted interpretation using the SmartPatch and TBConnect application may be used if supported by the findings of Sub-study 1 and approved for use in the trial. Participants requiring further clinical assessment will be referred or linked to the health facility, and eligible participants will be linked to tuberculosis preventive treatment according to national guidelines.

  • DeviceSmartPatch reading using the TBConnect AI-assisted interpretation

    The SmartPatch and AI-driven TBConnect application are used to support AI-assisted interpretation of the SIILTIBCY skin test. The SmartPatch is applied to the participant's forearm and linked to the TBConnect platform through a unique QR code. Images of the SIILTIBCY administration site are captured using TBConnect for AI-assisted interpretation.

06

What researchers measure

Primary outcomes

  1. Number of eligible contacts initiating tuberculosis preventive treatment per index TB patient

    Number of eligible close contacts who initiate tuberculosis preventive treatment (TPT) per enrolled index TB patient, compared across study arms. This outcome will be used to assess the effectiveness of integrating home-based SIILTIBCY testing and reading into contact investigation compared with standard of care.

    Time frame: From sub-study 2 initiation through study completion, approximately 15 months

Secondary outcomes

  1. Number of contacts identified per TB index patient

    Number of household or other close contacts identified per TB index patient. The number of contacts identified per index patient will be calculated at cluster level and compared across the three study arms.

    Time frame: From sub-study 2 initiation through study completion, approximately 15 months

  2. Proportion of estimated contacts identified

    Proportion of the estimated contacts of TB index patients who are identified through contact investigation. The proportion will be calculated for each cluster and compared across the three study arms.

    Time frame: From sub-study 2 initiation through study completion, approximately 15 months

  3. Proportion of estimated contacts screened for tuberculosis infection

    Proportion of estimated contacts who undergo tuberculosis infection (TBI) screening. For participants receiving SIILTIBCY, completion of the test requires interpretation within the protocol-defined 48-72-hour reading window after administration.

    Time frame: From sub-study 2 initiation through study completion, approximately 15 months

  4. Proportion of estimated contacts initiating tuberculosis preventive treatment

    Proportion of estimated contacts who initiate tuberculosis preventive treatment (TPT). TPT initiation is recorded using the treatment start date and will be compared across study arms.

    Time frame: From sub-study 2 initiation through study completion, approximately 15 months

  5. Proportion of estimated contacts completing tuberculosis preventive treatment

    Proportion of estimated contacts who complete tuberculosis preventive treatment (TPT). Treatment completion status and completion date will be recorded and the outcome compared across study arms.

    Time frame: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

  6. Occurrence of adverse events

    Proportion of participants experiencing one or more adverse events during TBI testing or TPT, including the type, severity and relatedness of adverse events to the intervention, where applicable.

    Time frame: Measured throughout the sub-study 2 implementation period (15 months) and until the last enrolled participant completes the 3-month tuberculosis preventive treatment course (approximately 18 months total)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying study publications may be made available in accordance with the TEST4TPT Data Management Plan, applicable ethical and legal requirements, and relevant data-sharing agreements. Shared datasets will exclude direct and indirect personal identifiers to minimise the risk of participant re-identification.

Supporting information: Study protocol, Statistical analysis plan, Analytic code

Time frame: IPD and supporting information will be made available following publication of the primary study findings. Study records will be retained for a minimum of five years after publication of the final study results, or longer where required by sponsor policies, institutional requirements, or applicable national ethics, data protection, or privacy regulations.

Access criteria: Fully de-identified datasets may be made openly available through a suitable trusted research data repository. Where participant-level datasets cannot be made openly accessible because of ethical or legal restrictions, qualified external researchers may request access by submitting a data access request describing the intended scientific use. Requests will be reviewed by the study Principal Investigators prior to approval. Access will be subject to participant consent, ethical approvals, institutional policies, sponsor requirements, and applicable data protection regulations.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2027; primary completion for Dec 2028, 20 months later.

Of 30 interventional studies with no phase under Latent Tuberculosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 47. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 29, 2026
First posted
Nov 13, 2026
StartEst.
Apr 2027
Primary completionEst.
Dec 2028
CompletionEst.
Apr 30, 2029
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07936643
Lead sponsor
KNCV Tuberculosis Foundation
Collaborators
National Institute for Medical Research, Tanzania, Fundação Manhiça, Barcelona Institute for Global Health, Makerere University Lung Institute, Mildmay Uganda Limited, London School of Hygiene and Tropical Medicine, Mwitikio wa Kudhibiti Kifua Kikuu na Ukimwi Tanzania
Responsible party
Christiaan Mulder (Coordinator, KNCV Tuberculosis Foundation) — Principal investigator
First posted
Nov 13, 2026
Start date
Apr 2027 (estimated)
Primary completion
Dec 2028 (estimated)
Completion
Apr 30, 2029 (estimated)
Last update
Nov 13, 2026

Study contacts

Christiaan Mulder, MsC PhD
Contact
christiaan.mulder@kncvtbc.org
+31 70 416 7234
Edine Tiemersma, Msc Phd
principal investigator · KNCV Tuberculosis Foundation

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion